| Name | 4-{(S)-2-(4-(4-chlorophenoxy)phenoxymethyl)pyrrolidin-1-yl}-1-butyric acid hydrochloride |
|---|---|
| Synonyms |
4-{(S)-2-[4-(4-Chloro-phenoxy)-phenoxymethyl]-pyrrolidin-1-yl}-butyric acid hydrochloride
DG051 (DG-051 (2S)-2-[[4-(4-Chlorophenoxy)phenoxy]methyl]-1-pyrrolidinebutanoic Acid Hydrochloride DG-051 HYDROCHLORIDE DG051,Aminoptidase,inhibit,DG 051,Inhibitor,DG-051 4-{(S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}butyric acid hydrochloride (S)-4-(2-((4-(4-Chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid hydrochloride DG051, 10 mM in DMSO DG 051 (HCl salt) 4-{(2S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}butyric acid hydrochloride 4-((S)-2-((4-(4-chlorophenoxy)phenoxy)Methyl)pyrrolidin-1-yl)butanoic acid hydrochloride |
| Description | DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 47 nM (LTA4H)[1] |
| In Vitro | DG051 is a potent inhibitor of LTA4H aminopeptidase activity against L-alanine p-nitroanilide (IC50=72 nM). DG051 inhibits human whole blood (HWB) with IC50 of 37 nM. As applied within the context of LTA4H inhibitor design, the chemistry team is able to design a potent DG051(Kd=26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke[1] DG-051 is a first-in-class small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), currently in Phase II clinical development for the prevention of heart attack[2]. |
| References |
| Molecular Formula | C21H25Cl2NO4 |
|---|---|
| Molecular Weight | 426.33400 |
| Exact Mass | 425.11600 |
| PSA | 59.00000 |
| LogP | 5.58020 |
| Storage condition | 2-8℃ |
| Precursor 1 | |
|---|---|
| DownStream 1 | |